2025 is in our view likely to see sales continue to grow (5% estimated vs 1.5% in 2024e) and margins continue to improve (53bp vs 14bp in 2024e), with the possible exception of a few companies (optimised margins or tariff risk). While some themes are likely to endure (US exposure, green capex, data centres, etc.), others will emerge (construction, discrete automation) or accelerate (semiconductors) over the year. In this context, our Top Picks are Alstom, Assa Abloy, Siemens and SKF. And we upgr...
L’année 2025 verra, selon nous, une poursuite de la croissance du CA (5% estimé vs 1.5% en 2024e) et de l’amélioration de la marge (53 pb vs 14 pb en 2024e), à l’exception possible de quelques sociétés (marge optimisée ou risque lié aux hausses des droits de douane). Si quelques thématiques devraient rester inchangées (exposition USA, Green Capex, datacenters, etc), d’autres émergeront (construction, discrete automation) ou accélèreront (semiconducteurs) au cours de l’année. Dans ce contexte, no...
We expect mixed Q4 results (due at 12:00 CET on 4 February), with improving momentum in Europe but still-sluggish North America. Romanian and US plants’ incremental volumes should pave the way for a stronger 2025e performance. We reiterate our HOLD but have reduced our target price to EUR8.3 (8.8) to reflect our c2% lower clean EBIT for 2025–2026e, driven by a slightly higher raw materials cost assumption. We continue to find the risk/reward in balance.
We have downgraded Sandvik to HOLD (BUY) and cut our target price to SEK220 (265). We lack confidence that the growth issues at Sandvik Manufacturing and Machining Solutions (SMM) will resolve in 2025 and, although Sandvik remains an obvious break-up story to us, it seems unlikely to materialise over our investment horizon, giving limited relevance to our cSEK240/share SOTP valuation. We favour Epiroc (BUY) over the SMR/SRP businesses for mining exposure.
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. The released shares relate to the 2022 legacy Chr. Hansen restricted stock units (RSU) program. Please see the full announcement in pdf. Attachment ...
Change to Novonesis’ Board of Directors Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision reflects her desire to focus on personal priorities. Cees de Jong, Chairman of the Board, comments: “Sharon James joined legacy Novozymes’ Board of Directors in 2020. She has made significant contributions to Novozymes, now Novonesis, shaping the organization’s direction. As leader of the Innovation Committee, Sharon has been instrumental in creating stro...
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 27, 2024, BlackRock, Inc. has adjusted its holding in Novonesis and now holds below 5% of total share capital attached to shares including share capital held through financial instruments (previously 5.05%). Attachments ...
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 25, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,879,950 shares, corresponding to 4.88% (previously 5.01%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instrumen...
Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments. Per November 21, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,464,124 shares, corresponding to 5.01% (previously 4.94%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instrumen...
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.